Theralase Technologies Inc Stock Price, News & Analysis

Theralase (TSXV: TLT) (OTCQB: TLTFF) completed enrollment and treatment of 90 patients in a multi-center Phase II registrational study for BCG-unresponsive NMIBC CIS using light-activated Ruvidar.

The study’s primary endpoint is efficacy; secondary is duration of response and tertiary is safety. Company expects study completion and preparation of Health Canada and FDA submissions in 2026.

Ferring Pharmaceuticals and Theralase (TSXV: TLT / OTCQB: TLTFF) announced a clinical development agreement dated January 9, 2026 to evaluate combination therapy in BCG-unresponsive non‑muscle invasive bladder cancer (NMIBC) CIS ± Ta/T1.

The study will add a new cohort to Theralase's Study II (NCT03945162) to test light‑activated Ruvidar (TLD‑1433) followed by Ferring's FDA‑approved intravesical gene therapy ADSTILADRIN (nadofaragene firadenovec‑vncg). Theralase remains sponsor; enrollment will begin in the U.S. with possible expansion pending written agreement. Study II has enrolled 88 of 90 patients with enrollment expected complete by 1Q2026 and follow‑up by 2Q2027.

Theralase (OTCQB: TLTFF) closed a non-brokered private placement on Dec 23, 2025, issuing 7,850,882 Units at CAN$0.17 per Unit for gross proceeds of approximately CAN$1,334,650. Each Unit includes one common share and one warrant exercisable at CAN$0.21 for 5 years. Proceeds will fund the ongoing Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study, working capital and general corporate purposes.

The company paid a finder's fee totalling CAN$31,658 (CAN$15,470 cash and CAN$16,188 in 95,221 common shares) and issued 186,221 non-transferable finder warrants exercisable at CAN$0.21 for 5 years. Securities are subject to a four-month plus one day hold expiring April 24, 2026, and the Offering awaits TSX Venture Exchange final acceptance.

Theralase (OTCQB: TLTFF, TSXV: TLT) commenced a non-brokered private placement to raise up to CAD 2,000,000 by issuing Units at CAD 0.17 each. Each Unit includes one common share and one warrant exercisable at CAD 0.21 for 60 months. Proceeds are earmarked to fund the ongoing Phase II NMIBC clinical study and working capital. Closing is expected the week of December 15, 2025, subject to TSXV approval. Finder compensation: 7% cash of gross proceeds plus non-transferable finder warrants equal to 7% of Units, exercisable at CAD 0.17 for 60 months. The company also mutually terminated the previously announced LIFE financing with Research Capital.

Theralase (OTCQB: TLTFF) will host a conference call on Nov 19, 2025 at 11:00 am ET to review interim Phase II Study II data for BCG-unresponsive NMIBC CIS and 3Q2025 financial results.

As of Nov 7, 2025, 88 of 90 patients treated (97.8% enrollment); 72 completed required visits. Interim efficacy: 64.3% CR (54/84) and 72.6% TR (61/84); at 450 days 40% CR durability (18/45). Company expects enrollment complete in 4Q2025 with data lock and regulatory submissions in 1Q2027.

Financials: nine-month revenue $590,573 (-5% YoY), net loss $3,435,145 (+3% YoY); company raised $672,627 via private placement and has $280,000 short-term loans at 15% interest.

Theralase (OTCQB:TLTFF) released unaudited condensed consolidated interim 3Q2025 financial statements and will host a conference call on Nov 19, 2025 at 11:00 am ET. For the nine months ended Sept 30, 2025 versus 2024: total revenue was $590,573 (down 5%), cost of sales $299,743 (51% of revenue, down 10%), and gross margin $290,830 (49% of revenue). Net loss was $3,435,145, a 3% increase, which included $708,521 in non-cash charges. Operational items: a $672,627 private placement (3,363,134 units at $0.20), extension of 1,840,000 warrants, and $280,000 short-term loans (15% interest).

Clinical: Study II is 97.8% enrolled (88/90); interim responses show CR 64.3%, Total Response 72.6%, and 40% CR durability at 450 days. Company expects enrollment complete in 4Q2025 and data lock/regulatory submissions in 1Q2027.

Theralase (OTCQB: TLTFF) reported preclinical data (Nov 3, 2025) showing X-ray-activated Rutherrin enhances radiation therapy in multiple cancer models.

Key findings: 100-fold greater cancer cell kill vs radiation alone; >10-fold tumor uptake over healthy brain; complete tumor regression and durable protection in colorectal models; increased ROS, immune cytokine activation, and modulation of drug efflux pathways. The company plans GLP toxicology in 2026 to support clinical development targeting GBM, NSCLC, pancreatic, lymphoma and colorectal cancers.

Theralase Technologies (OTCQB: TLTFF) has announced significant preclinical results for its antiviral candidate Ruvidar in treating Herpes Simplex Virus Type 1 (HSV-1). The peer-reviewed research demonstrates that Ruvidar is more effective than current gold standard treatments Acyclovir and Metformin, even without light activation.

Key findings show that Ruvidar effectively suppresses viral replication in infected cells and prevents infection spread to adjacent cells, while current treatments showed minimal effect post-infection. Notably, Ruvidar proved effective against Acyclovir-resistant HSV-1 mutants. The company plans to commence a Phase I/II adaptive clinical study in 2026 to evaluate Ruvidar's safety and efficacy in treating cold sore lesions.

Theralase Technologies (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on light, radiation, sound and drug-activated therapeutics for treating cancer, bacteria and viruses, has announced plans to extend its warrant expiration date. The company aims to extend 1,840,000 share purchase warrants from September 7th, 2025 to September 7th, 2028.

These warrants, originally issued on September 7th, 2023 through a private placement, are exercisable at CAN $0.35 per share. The extension is pending final approval from the TSX Venture Exchange.